Flat-Colour.png
 

1V Venture Credit Fund


The OneVentures Credit Fund launched in August 2018,  raising  up to $100M in funds available for high-growth technology companies.

The Fund is focused on rapidly growing companies that are differentiated through technological innovation, with strong revenue growth. In particular, OneVentures is looking for companies operating in the SaaS, fintech, marketplace and e-commerce spaces, who are led by exceptional founding teams and generating >$3-5M in revenue.

Venture credit is attractive to companies seeking a less dilutive financing option, or companies looking to incorporate venture credit within the funding mix of their capital raising round. It provides a longer capital runway, allowing companies more time to achieve important milestones before a subsequent round of financing. In the same way as our equity investments, the OneVentures team will continue to provide insight, network and strategic knowledge to the investee company.

The fund is seeking technology companies with a strong product market fit, investing $500K to $5M per company and making approximately 40 investments.

Airbnb host management company   $4M venture credit financing (June 2019)

Airbnb host management company

$4M venture credit financing (June 2019)

 
 
 
 

OneVentures Healthcare Fund III


In December 2016 OneVentures launched its $170M Healthcare Fund III. This Fund invests in therapeutics, devices and diagnostics at or near clinical development with a clear commercial, regulatory and reimbursement pathway; and well-defined value inflection and exit points on deal entry.

The fund will invest $10 to $20 million per company in Australian domiciled companies. The OneVentures team will provide support to drive these opportunities through the clinical, regulatory and reimbursement processes to achieve prominence in global markets.

The fund is licenced under the Commonwealth Government’s Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an $85 million license supported by matching capital from its private investor network. The BTF funding provides benefits to investors both during the investment phase and on realisation.

 
Food allergy therapeutics   Led $15M Series A (September 2016)

Food allergy therapeutics

Led $15M Series A (September 2016)

Medical device for treating vaginal dryness   Led $4M Series A (September 2018)

Medical device for treating vaginal dryness

Led $4M Series A (September 2018)

Total Artificial Heart (TAH) to replace complete function of a patient’s failing heart   Participated in Series A financing to fund the development of the external controller for the TAH (February 2018)

Total Artificial Heart (TAH) to replace complete function of a patient’s failing heart

Participated in Series A financing to fund the development of the external controller for the TAH (February 2018)

Small molecule drugs for the treatment of fibrosis   Co-led US$10M Series C (November 2018)

Small molecule drugs for the treatment of fibrosis

Co-led US$10M Series C (November 2018)

Drugs for the treatment of autoimmune disease   Led $2M Series A (August 2018)

Drugs for the treatment of autoimmune disease

Led $2M Series A (August 2018)

 
 

OneVentures Innovation and Growth Fund II

 

The OneVentures Innovation and Growth Fund II was launched in October 2014 with $75M in funds available for investment in technology and healthcare businesses.

Fund II is focused on later stage companies seeking growth and development capital including for offshore expansion. Fund II is currently seeking technology companies with a strong product market fit and a clear path to revenue of $3 to 5M over the next 12 months. In particular, we are looking at investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success. The fund looks to invest on average $5M and up to $10M into any one company.

 
Cloud-based HR platform   Led $4.5M Series A (July 2016)  Co-led with Seek Ventures $8M Series B (March 2018)

Cloud-based HR platform

Led $4.5M Series A (July 2016)

Co-led with Seek Ventures $8M Series B (March 2018)

Cancer DNA diagnostics   US$15M Series A (April 2016)

Cancer DNA diagnostics

US$15M Series A (April 2016)

Microprojection array (Nanopatch) for intradermal vaccine delivery   Led syndicate for $15M Series A financing (August 2011)  Led $33M Series B financing (February 2015)   Visit website

Microprojection array (Nanopatch) for intradermal vaccine delivery

Led syndicate for $15M Series A financing (August 2011)

Led $33M Series B financing (February 2015)

Visit website

 
Photo-realistic holographic technology platform   Contributed to a US$1527M Series B financing led by Time Warner Investments (November 2016)

Photo-realistic holographic technology platform

Contributed to a US$1527M Series B financing led by Time Warner Investments (November 2016)

Wearables for the vulnerable   Led $4M Series A (December 2015)

Wearables for the vulnerable

Led $4M Series A (December 2015)

Food allergy therapeutics   Led $15M Series A (September 2016)

Food allergy therapeutics

Led $15M Series A (September 2016)

 
 

OneVentures Innovation Fund I

 

The OneVentures Innovation Fund is a $40M venture capital fund established to provide capital and expertise to early stage (seed and Series A companies). This fund was launched in 2010 with the Commonwealth Government committing $20M from its Innovation Investment Fund programme matched by $20M capital from private sector investors. Capital from this fund is fully deployed.

Adaptive e-learning platform   Led Series A (October 2011)  $10M Series B (December 2013)  Led $5M C-Note financing (July 2016)  US$7.5M Series C (January 2018)   Visit website

Adaptive e-learning platform

Led Series A (October 2011)

$10M Series B (December 2013)

Led $5M C-Note financing (July 2016)

US$7.5M Series C (January 2018)

Visit website

Microprojection array (Nanopatch) for intradermal vaccine delivery   Led syndicate for $15M Series A financing (August 2011)  Led $33M Series B financing (February 2015)   Visit website

Microprojection array (Nanopatch) for intradermal vaccine delivery

Led syndicate for $15M Series A financing (August 2011)

Led $33M Series B financing (February 2015)

Visit website

Oncology information systems   Led acquisition by The Citadel Group (ASX:CGL) for ~$10.8M (September 2017)

Oncology information systems

Led acquisition by The Citadel Group (ASX:CGL) for ~$10.8M (September 2017)

Single application head lice treatment   Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M (September 2015)

Single application head lice treatment

Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M (September 2015)

Peak3 - OneVentures portfolio company
Video engagement platform   Led $4.9M Series A with participation by Intel and Warner Music (October 2014)  Led Series A2 investment into Incoming Media (July 2017)  Acquired by My Mobile Data (December 2017)   Visit website

Video engagement platform

Led $4.9M Series A with participation by Intel and Warner Music (October 2014)

Led Series A2 investment into Incoming Media (July 2017)

Acquired by My Mobile Data (December 2017)

Visit website

Paloma - OneVentures portfolio company
Building energy management software   Investment realised, IRR 70% (December 2012)

Building energy management software

Investment realised, IRR 70% (December 2012)

Beasy - OneVentures portfolio company